{
    "2018-06-29": [
        [
            {
                "time": "",
                "original_text": "[强于大市评级]深度*行业*医药生物行业2018年中期策略：调整之后板块出现战略性买入机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2018年中期策略",
                        "调整",
                        "战略性买入机会"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[优异评级]医药生物行业2018半年度策略：医改落地 机会绽放",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2018半年度策略",
                        "医改",
                        "机会绽放"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物大涨5.64%，报20.05元",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "大涨",
                        "5.64%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级]创新药产业深度报告暨2018年中期投资策略：医药创新的收获期逐渐来临",
                "features": {
                    "keywords": [
                        "创新药",
                        "2018年中期投资策略",
                        "医药创新",
                        "收获期"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "创新药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}